A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis

Rubén Burgos-Vargas, Shirley M L Tse, Gerd Horneff, Aileen L Pangan, Jasmina Kalabic, Sandra Goss, Kristina Unnebrink, Jaclyn K Anderson, Rubén Burgos-Vargas, Shirley M L Tse, Gerd Horneff, Aileen L Pangan, Jasmina Kalabic, Sandra Goss, Kristina Unnebrink, Jaclyn K Anderson

Abstract

Objective: Enthesitis-related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA.

Methods: This is a phase III, multicenter, randomized double-blind study in patients ages ≥6 to <18 years with ERA treated with adalimumab (24 mg/m(2) , maximum dose 40 mg every other week) or placebo for 12 weeks, followed by up to 192 weeks of open-label adalimumab. The primary end point was percent change from baseline in number of active joints with arthritis (AJC) at week 12. Samples were collected to determine adalimumab serum concentrations. Adverse events (AEs) were assessed throughout the study.

Results: Forty-six patients were randomized (31 adalimumab/15 placebo). At baseline, mean age was 12.9 years, mean duration of ERA symptoms was 2.6 years, mean AJC was 7.8, and mean enthesitis count was 8.1. Mean percent change from baseline in AJC at week 12 was greater in the adalimumab group versus placebo (-62.6% versus -11.6%; P = 0.039). Most secondary variables favored adalimumab versus placebo at week 12. Treatment response further increased with continued adalimumab therapy through week 52. Mean steady-state adalimumab serum concentrations were 7.5-11.8 μg/ml, similar to patients age ≥2 years with polyarticular JIA. AE rates were similar between placebo and adalimumab: any AE (53.3% versus 67.7%), serious AEs (0% versus 3.2%), and infectious AEs (20.0% versus 29.0%).

Conclusion: Adalimumab reduced signs and symptoms of ERA at week 12, with improvement sustained through week 52. The safety profile was consistent with previous adalimumab studies.

Trial registration: ClinicalTrials.gov NCT01166282.

© 2015 The Authors. Arthritis Care & Research is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.

Figures

Figure 1
Figure 1
Patient disposition through week 52. DB = double‐blind; * = a patient may have had more than 1 reason for study discontinuation.
Figure 2
Figure 2
Clinical response during the 12‐week, double‐blind period and 40‐week, open‐label adalimumab period. A, mean percent change from baseline in active joints with arthritis (AJC) by treatment over time through week 52; * indicates P = 0.039, adalimumab versus placebo. B, mean active joint count by treatment over time through week 52. C, mean enthesitis count by treatment over time through week 52. D, mean tender joint count by treatment over time through week 52. Analyses are last observation carried forward.
Figure 3
Figure 3
Kaplan Meier curves for time to achieve joint or enthesitis counts = 0, from first adalimumab injection through week 52. A, time to achieve swollen joint count (SJC) = 0. B, time to achieve tender joint count (TJC) = 0. C, time to achieve total enthesitis count (EC) = 0. N = number of patients.

References

    1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
    1. Flato B, Hoffmann‐Vold AM, Reiff A, Forre O, Lien G, Vinje O. Long‐term outcome and prognostic factors in enthesitis‐related arthritis: a case‐control study. Arthritis Rheum 2006;54:3573–82.
    1. Sarma PK, Misra R, Aggarwal A. Outcome in patients with enthesitis related arthritis (ERA): juvenile arthritis damage index (JADI) and functional status. Pediatr Rheumatol Online J 2008;6:18.
    1. Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD. Juvenile‐onset ankylosing spondylitis is associated with worse functional outcomes than adult‐onset ankylosing spondylitis. Arthritis Rheum 2005;53:445–51.
    1. Tupper SM, Rosenberg AM, Pahwa P, Stinson JN. Pain intensity variability and its relationship with quality of life in youths with juvenile idiopathic arthritis. Arthritis Care Res 2013;65:563–70.
    1. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M, et al. Long‐term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392–401.
    1. Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. Enthesitis‐related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 2012;39:2341–51.
    1. Tse SM, Burgos‐Vargas R, Colbert RA. Juvenile spondyloarthritis treatment recommendations. Am J Med Sci 2012;343:367–70.
    1. Burgos‐Vargas R, Vazquez‐Mellado J, Pacheco‐Tena C, Hernandez‐Garduno A, Goycochea‐Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies [abstract]. Ann Rheum Dis 2002;61:941–2.
    1. Burgos‐Vargas R, Casasola‐Vargas JC, Gutierrez‐Suarez R, Vazquez‐Mellado J. An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial to assess the long‐term efficacy and safety of infliximab in juvenile‐onset spondyloarthritis (Jo‐Spa) [abstract]. Arthritis Rheum 2008;58 Suppl:S578.
    1. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis‐related arthritis. J Rheumatol 2004;31:2055–61.
    1. Tse SM, Burgos‐Vargas R, Laxer RM. Anti–tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005;52:2103–8.
    1. Hugle B, Burgos‐Vargas R, Inman RD, O'Shea F, Laxer RM, Stimec J, et al. Long‐term outcome of anti‐tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 2014;32:424–31.
    1. Tse SM, Laxer RM, Babyn PS, Doria AS. Radiologic improvement of juvenile idiopathic arthritis enthesitis–related arthritis following anti–tumor necrosis factor‐α blockade with etanercept. J Rheumatol 2006;33:1186–8.
    1. Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFα antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009;76:24–7.
    1. Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int 2004;24:173–6.
    1. Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppebnreijs EP, et al. Tumor necrosis factor–blocking agents for children with enthesitis‐related arthritis: data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010. J Rheumatol 2011;38:2258–63.
    1. Burgos‐Vargas R, Casasola‐Vargas J, Gutierrez‐Suarez R, Vazquez‐Mellado J. Efficacy, safety, and tolerability of infliximab in juvenile‐onset spondyloarthropathies (JO‐SpA): results of the three‐month, randomized, double‐blind, placebo‐controlled trial phase [abstract]. Arthritis Rheum 2007;56 Suppl:S319.
    1. Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle‐Deschner J, Tzaribacev N, et al. Double‐blind, placebo‐controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012;14:R230.
    1. Horneff G, Burgos‐Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open‐label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis‐related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2014;73:1114–22.
    1. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 2011;50:214–21.
    1. Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF‐α inhibitor therapy for juvenile idiopathic arthritis: enthesitis‐related arthritis predicts persistent active disease. J Rheumatol 2011;38:2675–81.
    1. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–20.
    1. Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012;31:1713–21.
    1. Kingsbury DJ, Bader‐Meunier B, Patel G, Aroro V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol 2014;33:1433–41.
    1. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2006;54:2136–46.
    1. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non‐radiographic axial spondyloarthritis: results of a randomised placebo‐controlled trial (ABILITY‐1). Ann Rheum Dis 2013;72:815–22.
    1. Heuft‐Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
    1. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68:948–53.
    1. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
    1. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.
    1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002;29:1520–30.
    1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767–78.
    1. Boiu S, Marniga E, Bader‐Meunier B, Mouy R, Compeyrot‐Lacassagne S, Quartier P, et al. Functional status in severe juvenile idiopathic arthritis in the biologic treatment era: an assessment in a French paediatric rheumatology referral centre. Rheumatology (Oxford) 2012;51:1285–92.
    1. Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis: International League of Associations for Rheumatology. J Rheumatol 2000;27:1069–72.
    1. Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006;33:1377–81.
    1. Stabile A, Avallone L, Compagnone A, Ansuini V, Bertoni B, Rigante D. Focus on juvenile idiopathic arthritis according to the 2001 Edmonton revised classification from the International League of Associations for Rheumatology: an Italian experience. Eur Rev Med Pharmacol Sci 2006;10:229–34.
    1. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001;28:845–53.
    1. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long‐term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517–24.
    1. Windschall D, Muller T, Becker I, Horneff G. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis‐related arthritis and psoriatic arthritis. Clin Rheumatol 2015;34:61–9.
    1. Burgos‐Vargas R, Vazquez‐Mellado J. The early clinical recognition of juvenile‐onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:835–44.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다